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Male sex development and growth occur in response to high
affinity androgen binding to the androgen receptor (AR). In
contrast to complete amino acid sequence conservation in the
AR DNA and ligand binding domains among mammals, a pri-
mate-specific difference in the AR NH2-terminal region that
regulates the NH2- and carboxyl-terminal (N/C) interaction
enables direct binding to melanoma antigen-A11 (MAGE-11),
an AR coregulator that is also primate-specific. Human, mouse,
and rat AR share the same NH2-terminal 23FQNLF27 sequence
that mediates the androgen-dependent N/C interaction. How-
ever, themouse and rat AR FXXLFmotif is flanked by Ala33 that
evolved to Val33 in primates. Human AR Val33 was required to
interact directly with MAGE-11 and for the inhibitory effect of
the AR N/C interaction on activation function 2 that was
relieved by MAGE-11. The functional importance of MAGE-11
was indicated by decreased human AR regulation of an andro-
gen-dependent endogenous gene using lentivirus short hairpin
RNAs and by the greater transcriptional strength of human
compared with mouse AR. MAGE-11 increased progesterone
and glucocorticoid receptor activity independently of binding
an FXXLFmotif by interacting with p300 and p160 coactivators.
We conclude that the coevolution of the AR NH2-terminal
sequence and MAGE-11 expression among primates provides
increased regulatory control over activation domain domi-
nance. Primate-specific expression of MAGE-11 results in
greater steroid receptor transcriptional activity through direct
interactions with the human AR FXXLF motif region and indi-
rectly through steroid receptor-associated p300 and p160
coactivators.
Androgen receptor (AR)2 regulation of gene transcription is
required for male reproductive development and function. AR
is a ligand-dependent transcription factor activated by binding
testosterone, a major circulating male steroid hormone, or
by dihydrotestosterone (DHT), the more potent 5-reduced
metabolite of testosterone. Evolution of AR amongmammals is
characterized by complete amino acid sequence conservation
in the central DNA binding domain that interacts with andro-
gen response elementDNAand in the carboxyl-terminal ligand
binding domain that binds androgens with high affinity and
specificity (1). Strict sequence conservation in these regions
reflects the rigid structural requirements for DNA and hor-
mone binding. In contrast, the AR NH2-terminal region,
although also required for AR transcriptional activity, is largely
unstructured and less well conserved (2). The human ARNH2-
terminal region contains activation function 1 (AF1) between
amino acid residues 142–337 (3) preceded by a polymorphic
CAG-encoded glutamine repeat that expanded during primate
evolution (1). Mechanisms involved in AF1 and glutamine
repeat function remain to be established. Expansion of the glu-
tamine repeat length to more than 39 residues results in the
adult onsetmusclewasting disease known as spinal bulbarmus-
cular atrophy (4). A similar glutamine repeat in rat and mouse
AR is shifted in position in the NH2-terminal region relative to
human AR (5).
The mammalian AR NH2-terminal region also contains a
conserved 23FQNLF27 sequence that binds activation function
2 (AF2) in the AR ligand binding domain to mediate the andro-
gen-dependent ARNH2- and carboxyl-terminal (N/C) interac-
tion (6, 7). AnNH2-terminal 433WHTLF437WXXLFmotif con-
tributes to the human AR N/C interaction and transcriptional
activity (6–8). The functional importance of the intermolecu-
lar AR N/C interaction is indicated by a dependence on high
affinity androgen binding, its requirement for optimal gene
transcription, and inhibition of the N/C interaction by classical
AR antagonists (7, 9–12). There are also naturally occurring
human AR single amino acid mutations that cause partial
androgen insensitivity and disrupt theARN/C interaction even
though high affinity androgen binding is maintained (13–20).
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The androgen-dependent human AR N/C interaction reduces
p160 coactivator binding to AF2 in the ligand binding domain
(21), which suggests regulation of activation domain domi-
nance. p160 coactivator binding to AF2 is increased by mela-
noma antigen-A11 (MAGE-11), an AR coregulator that binds
the human AR FXXLF motif region in a manner competitive
with the N/C interaction to expose AF2 for increased p160
coactivator recruitment (22). MAGE-11 also interacts with
p300 and p160 coactivators (23, 24).
Studies in this report address the functional consequences of
amino acid sequence differences in the AR NH2-terminal region
amongprimates and lowermammals that parallel the evolution of
MAGE-11 expression. Our findings suggest that the primate-spe-
cific expression of MAGE-11 increases AR transcriptional
strength through direct binding to the human AR FXXLF motif
region. We provide evidence that MAGE-11 also functions as a
more general transcriptional coregulator through interactions
with steroid receptor-associated p300 and p160 coactivators.
EXPERIMENTAL PROCEDURES
Expression Vectors—Previously described plasmids include
pCMV-hAR that codes for full-length human AR (hAR) (25)
and L26A,F27A (6, 23);120–472, 1–660 (3), 1–503 (10), 507–
919 (3), and K720A mutants (14); GAL-hAR-(658–919) (26)
and -(4–52); pSG5-MAGE-(1–429) that codes for full-length
human MAGE-11; GAL-MAGE-(2–429) (GAL-MAGE) and
-(112–429); pCMV-FLAG-MAGE-(2–429) (FLAG-MAGE)
(27); pVP16-CT-MAGE-(2–429) (VP-MAGE) andVP-MAGE-
(112–429) with VP16 activation domain residues 446–490
(Clontech) (22); pNLVP16-hAR-(1–660) (13) and L26A,F27A
mutant (6) with VP16 activation domain residues 411–456;
pCMV-human glucocorticoid receptor (hGR) (21); pCMV-hu-
man progesterone receptor (hPR)-B-(1–688) and pCMV-hGR-
(1–550) NH2-terminal and DNA binding domains (22); pSG5-
HA-p300 (24); and pSG5-transcriptional intermediary factor 2
(TIF2) (14, 28). Reporter vectors used include human prostate-
specific antigen-enhancer-luciferase (PSA-Enh-Luc) (24, 29),
5XGAL4Luc3 (24), rat probasin BH500-Luc (30, 31), and
mouse mammary tumor virus (MMTV) luciferase.
pCMV-hAR120–472-V33A, -S94A, and pNLVP-hAR-
(1–660)-V33A were created by QuikChange site-directed
mutagenesis (Stratagene). pCMV-hAR-V33A was created by
double PCRmutagenesis. pCMV-GR-(399–795) coding for the
rat glucocorticoid receptor (GR) DNA and ligand binding
domains was created by PCR amplification and subcloning into
EcoRI andBamHI sites of pCMV5.Humanprogesterone recep-
tor (PR) p5M-hPR-B contains an EcoRI fragment of pSG5-
hPR-B (providedbyPierreChambon)cloned into theEcoRI siteof
pCMV5 with a HindIII and BamHI deletion in the polylinker
region. Human PR-B DNA and ligand binding domains were
expressed from pcDNA-myc-PR-B-(486–933) that contains a
PCR-amplified EcoRI and internal HindIII fragment of PR-B
cloned in pcDNA3-myc-PR-B-(550–933) digested with the same
enzymes.
Full-length mouse AR (mAR) pCMV-mAR was created by
subcloning full-length C57BL/6 mouse AR sequence from
pCMV-HA-mAR (provided byNormanM.Greenberg) into the
EcoRI and BamHI sites of pCMV5. pCMV-mAR-L26A,F27A
was a triple ligation of pCMV5 EcoRI and BamHI, pCMV-
mAR-(1–285)-L26A,F27A EcoRI and MluI, and pCMV5-mAR
MluI and BamHI fragments. pCMV-mAR-(1–640) contains a
PCR-amplified EcoRI and BamHI fragment of pCMV-mAR
cloned in the same sites of pCMV5. pCMV-mAR-(487–899),
which corresponds to hAR-(507–919), and pCMV-mAR-(487–
899)-K700A contain EcoRI and BamHI fragments from
PCR-amplified pCMV-mAR with an added ATG initiating
methionine sequence inserted in the same sites of pCMV5.
pCMV-mAR-A33V was a triple ligation of pCMV5 EcoRI and
BamHI, pCMV-mAR-(1–640)-A33V EcoRI and HindIII, and
pCMV5-mAR HindIII and BamHI fragments.
pCMV-mAR101–452 corresponds to hAR120–472 and
was a triple ligation of pCMV-mAR-(1–640)101–452 EcoRI
and HindIII, pCMV-mAR HindIII and BamHI, and pCMV5
EcoRI and BamHI fragments. pCMV-mAR101–452-
L26A,F27A was a triple ligation of PCR-amplified mAR-(1–
640)-101–452,L26A,F27A EcoRI and HindIII, pCMV-mAR
BamHI andHindIII, and pCMV5 EcoRI and BamHI fragments.
pCMV-mAR101–452-A33V was a triple ligation of pCMV-
mAR-(1–640)101–452-A33V EcoRI and HindIII, pCMV-
mAR BamHI and HindIII, and pCMV5 EcoRI and BamHI
fragments. pCMV-mAR101–452-K700A was a triple liga-
tion of EcoRI- and BamHI-digested pCMV5, an EcoRI and
HindIII fragment of pCMV-mAR-(1–640)101–452, and a
HindIII and BamHI fragment of pCMV-mAR-(487- 899)-
K700A. pCMV-mAR101–452-A33V,K700A was the same
except with an EcoRI and HindIII fragment of
pCMV-mAR-(1–640)101–452-A33V.
GAL-mAR-(4–52) contains an EcoRI and NdeI PCR-ampli-
fied fragment from pCMV-mAR cloned in the same sites of
GALO. pNLVP16-mAR-(2–640) and rat AR (rAR) pNLVP16-
rAR-(2–643) were created by subcloning corresponding PCR-
amplified regions of pCMV-mARandpCMV-rAR (32) into SalI
and XbaI sites of pNLVP16. All PCR-amplified regions were
verified by DNA sequencing.
DNA Transfection and Gene Expression Studies—Mamma-
lian two-hybrid assays were performed in HeLa cells (5  104/
well) (26) in 12-well plates transfected using FuGENE 6 (Roche
Applied Science), expression vector DNA, and 0.1 g/well
5XGAL4Luc reporter gene. The day after transfection, cells
were transferred to serum-free medium and incubated for 24 h
in the absence and presence of DHT. AR transcription assays in
HeLa cells utilized wild-type and mutant pCMV-hAR and
pCMV-mAR and 0.1 or 0.25 g/well PSA-Enh-Luc, BH500-
Luc that contains the 426 to 28 rat probasin promoter pro-
vided by Robert J. Matusik (30, 31), or MMTV-Luc. Cells were
harvested in 0.25ml of lysis buffer containing 1%Triton X-100,
2 mM EDTA, and 25 mM Tris phosphate, pH 7.8. Transcription
assays in CV1 cells (4  105/6-cm dish) were performed using
calcium phosphate precipitation (21). Immediately after trans-
fection and 24 h later, cells were incubated for 24 h in serum-
free phenol red-free medium in the absence and presence of
DHT and harvested in 0.5 ml of lysis buffer. Luciferase activity
was measured using an automated Lumistar Galaxy luminom-
eter (BMG Labtech), and values (mean  S.E.) are representa-
tive of at least three independent experiments. The siRNA oli-
gonucleotide experiments were performed in HeLa cells (2 
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105/well) in 6-well plates and in COS cells (2  106 cells/10-cm
dish) using p300 siRNAs, nonspecific siRNA-3 (Dharmacon
RNA Technologies), and Lipofectamine 2000 (Invitrogen) in
the absence of antibiotics (24).
Immunoblot Analysis—Immunoblots were performed by
transfecting monkey kidney COS cells (2  106/10-cm dish)
using DEAE-dextran (26, 33). After 24 h, cells were placed in
serum-free, phenol red-free medium with and without DHT.
The next day cells were harvested in immunoblot lysis buffer
containing 1% Triton X-100, 1% sodium deoxycholate, 0.1%
SDS, 0.15 M NaCl, 2 mM EDTA, 0.05 mM NaF, 2 mM sodium
vanadate, and 50 mM Tris-HCl, pH 7.5 with 1 mM phenylmeth-
ylsulfonyl fluoride, 1 mM dithiothreitol, and Complete protease
inhibitor mixture (Roche Applied Science). In some experi-
ments, cells were incubated for 24 h with 1 MMG132 proteo-
some inhibitor (Sigma). Cell extracts were analyzed in poly-
acrylamide gels containing SDS and probed using the following
antibodies: rabbit anti-VP16 activation domain (Abcam
ab4809; 1:1000 dilution), rabbit anti-GAL4 DNA binding
domain (Santa Cruz Biotechnology sc-577; 1:500 dilution), rab-
bit anti-human AR32 (0.4 g/ml) and AR52 (10 g/ml) anti-
peptide immunoglobulin G (25), mouse anti--actin (Abcam;
1:5000 dilution); affinity-purified rabbit polyclonal human
p300 (C-20) antibody (Santa Cruz Biotechnology sc-585; 1:75–
200 dilution), mouse anti-TIF2 (BD Transduction Laborato-
ries; 1:100–250 dilution), rabbit polyclonal GR antibody (Santa
Cruz Biotechnology sc-1003; 1:200), and rabbit polyclonal PR
antibody (Santa Cruz Biotechnology sc-7208; 1:200). Endoge-
nousMAGE-11was detected in transblots using 10g of rabbit
polyclonal antibody-1 prepared against baculovirus-expressed
and purified FLAG-tagged human MAGE-11 and 10 g of
MAGE-Ab-94–108 anti-peptide immunoglobulin G (34). Gels
were calibrated using EZ-Run prestained Rec protein ladder
(Fisher Bioreagents) and analyzed for chemiluminescence
(SuperSignalWest Dura Extended Duration Substrate, Pierce).
Immunoprecipitation was performed by expressing FLAG
empty vector or FLAG-MAGEwith pCMV-hAR, pCMV-mAR,
p5M-hPR-B, or pCMV-hGR in COS cells (2  106/10-cm dish)
usingDEAE-dextran transfection (26, 33). Cell lysates from two
10-disheswere extracted in 0.25ml of lysis buffer containing 1%
Triton X-100, 0.5% deoxycholate, 0.15 M NaCl, 0.05 M NaF, 2
mMEDTA, 2mM sodiumvanadate, and 50mMTris, pH7.6with
1 mM phenylmethylsulfonyl fluoride, 1 mM dithiothreitol, and
Complete protease inhibitor mixture (Roche Applied Science);
diluted 4-fold with the same buffer without deoxycholate; and
precleared for 15 min at 4 °C with 0.1 ml of Sepharose CL-4B
(Sigma). Cell extracts were transferred to 15 l of anti-FLAG
M2-agarose (Sigma) and incubated for 2 h at 4 °C. Sampleswere
pelleted; washed with lysis buffer without deoxycholate; resus-
pended in 0.05 ml of 2 SDS buffer containing 3.3% SDS, 10%
2-mercaptoethanol, 10% glycerol, and 0.12 M Tris-HCl, pH 6.8;
incubated for 5 min at 90 °C; and analyzed on immunoblots as
above.
GenomeAnalysis ofMAGE Families and Two-hybrid Screens—
The human MAGE-11 amino acid sequence was compared
with the NCBI BLASTAssembled RefSeq Database for human,
Rhesus macaque, mouse and rat genomes. We obtained no
experimental evidence for human MAGE-11 isoform B indi-
cated by the human genome database.
The Clontech Mate and Plate yeast two-hybrid screen was
performed by preparing mouse testis complementary DNA
(cDNA) pool using SMART cDNA synthesis technology,
recombination with Matchmaker prey vector pGADT7-Rec,
and transformation in yeast strain Y187. Two independent
screens of 2  108 colonies of a mouse testis library were per-
formed using GAL-mAR-(4–52) or GAL-mAR-(2–285) as bait
in yeast strain Y2HGold. Selection parameters included resis-
tance to aureobasidin A, X--Gal blue colony formation, and
growth in the absence of histidine or adenine. Screening using
GAL-mAR-(4–52) as bait yielded 11 positive independent
clones compared with 17 positive independent clones using
GAL-mAR-(2–285) as bait. None of the identified protein
interactions with mouse AR were FXXLF motif-dependent.
Lentivirus Transduction and Real Time RT-PCR—LAPC-4
human prostate cancer cells were maintained in RPMI 1640
medium containing 10% fetal calf serum (Cellgro), 1 nM R1881
(PerkinElmer Life Sciences), 2 mM L-glutamine, penicillin, and
streptomycin (Invitrogen). HeLa-AR1C-PSA-Luc-A6 cells sta-
bly express humanAR and the PSA-Luc reporter gene andwere
maintained in minimum Essential medium (Invitrogen) con-
taining 10% fetal calf serum, 2 mM L-glutamine, penicillin,
streptomycin, 500g/mlGeneticin (G418, Invitrogen), and 100
g/ml hygromycin B (Roche Applied Science). MAGE-11 len-
tivirus short hairpin RNA (shRNA)-169, -827, -947, and -964;
human AR shRNA-5; the empty vector shRNA nonspecific
siRNA-1; and 18-bp-spacer nonspecific siRNA-2 were created
using the Open Biosystems TRC1 shRNA libraries following
standard protocols. LAPC-4 (3  106/well) or HeLa-AR-PSA
cells (2  105/well) in 6-well plates were used without virus or
transduced with 0.15 ml (LAPC-4 cells) or 0.025 ml (HeLa-AR
cells) of HEK-293 cell supernatant containing 106 lentivirus
virus particles/ml. After 48 h, cells were passaged into selection
medium containing 3 g/ml puromycin dihydrochloride (Cell-
gro) in 10-cm dishes for immunoblot analysis and 6-cm dishes
for RT-PCR analysis. After 9 days in selectionmedium, cells for
RT-PCRanalysiswere incubated for 24 h inmediumcontaining
10% charcoal-stripped fetal calf serum with and without DHT.
Cells for immunoblots were incubated with and without 10 nM
DHT, extracted in lysis buffer, and analyzed.
Total RNAwas extracted using 1ml of TRIzol reagent (Invit-
rogen)/6-cm dish followed by chloroform/isopropanol extrac-
tion. First strand cDNA was prepared using SuperScript II
reverse transcriptase (Invitrogen). Real time PCR was per-
formed using an Eppendorf Realplex4Mastercycler and Quan-
tiTect SYBR Green PCR kit (Qiagen) in 20-l reactions. Pepti-
dylprolyl isomerase A served as a housekeeping control gene.
Peptidylprolyl isomerase A forward primer 5-ATCTTGTC-
CATGGCAAATGC-3 and reverse primer 5-GCCTCCA-
CAATATTCATGCC-3 amplify a 134-bp 371–505-nucleotide
fragment overlapping the exon 4 and 5 junction coding for
amino acid residues 123–169 (GenBankTM accession number
NM_021130). PSA forward primer 5-CTCATCCTGTCTCG-
GATTGT-3 and reverse primer 5-ATGAAACAGGCTGT-
GCCGAC-3 amplify a 189-bp 99–287-nucleotide fragment
overlapping the exon 2 and 3 junction that codes for amino acid
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residues 20–82 (GenBank accession number NM_001648).
MAGE-11 forward primer 5-GGAGACTCAGTTCCGCA-
GAG-3 and reverse primer 5-TGGGACCACTGTAGTT-
GTGG-3 amplify a 63-bp 123–185-nucleotide fragment cod-
ing for amino acid residues 24–43 with the probe centered at
nucleotide 154 (GenBank accession number AY747607.1)
overlapping the exon 2 and 3 junction (22, 34). PCRs (20 l)
contained 4l of cDNA from0.1g of total RNA, 10l of SYBR
Green Master Mix, 2 l of 2 M forward and reverse primers,
and 2 l of RNase-free water. PCR conditions were one cycle at
94 °C for 20 min and 55 cycles at 94 °C for 40 s, 57 °C for 40 s,
and 72 °C for 40 s. 10-fold serial dilutions of cDNAwere ampli-
fied in triplicate to generate standard curves. UnknownmRNA
levelswere extrapolated based on standard curves andCt values
normalized to peptidylprolyl isomerase A.
HeLa-AR-PSA-Luc-A6 cell growth assays were performed
by plating 5000 cells/well of 24-well plates in 0.5 ml of medium
containing 10% fetal bovine serum. Cells were incubated for
increasing times and assayed using the cell counting kit
(Dojindo Laboratories). WST-8 reagent (0.02 ml) was added to
0.2 ml of serum-free medium and incubated for 2.5 h at 37 °C.
Optical density measurements were determined at 485 nm.
RESULTS
Species-specific AR FXXLFMotif Interactions—TheARNH2-
terminal FXXLF motif sequence 23FQNLF27 is conserved
among mammals with the hydrophobic character maintained
throughout lower vertebrates including fish (Fig. 1A) (7, 35).
However, the sequence flanking the AR FXXLF motif differs
with Ala33 inmouse, rat, and other lower vertebrates evolved to
Val33 in human, chimpanzee, Rhesus macaque, lemur, and
other primates (Fig. 1, A and B). Human AR Val33 is in a pre-
dicted -helical region that extends from the FXXLFmotif that
interacts with AF2 in the ligand binding domain bound to a
high affinity androgen. AR FXXLF motif binding to AF2 com-
petes with AR FXXLFmotif binding toMAGE-11, a human AR
coregulator (22, 36).
Species-specific differences in the AR N/C interaction and
AR FXXLF motif binding to MAGE-11 were investigated for
human, rat, and mouse AR in mammalian two-hybrid assays.
The androgen-dependent N/C interaction between the AR
FXXLF motif and AF2 in the ligand binding domain (6) was
assayed in the absence and presence of DHT using GAL-hAR-
(658–919) in which the GAL4 DNA binding domain was
expressed as a fusion protein with the AR ligand binding
domain conserved in human, mouse, and rat (5).
In the presence of 10 nM DHT, GAL-hAR-(658–919) inter-
actedwith humanVP-hAR-(1–660),mouseVP-mAR-(2–640),
and rat VP-rAR-(2–643), which are corresponding regions of
the AR NH2-terminal and DNA binding domains fused to the
VP16 activation domain (Fig. 2A). VP-hAR-(1–660) also inter-
acted in two-hybrid assays with full-length GAL-MAGE and
the GAL-MAGE-(112–429) carboxyl-terminal fragment that
contains the F-box-like binding region for the human AR
FXXLF motif (22, 23). However, there was essentially no inter-
action of GAL-MAGE or GAL-MAGE-(112–429) with mouse
VP-mAR-(2–640) or rat VP-rAR-(2–643) (Fig. 2B).
The inability of themouse and rat AR FXXLFmotif region to
bind MAGE-11 was also evident using the mouse GAL-mAR-
(4–52) FXXLF motif peptide that differs from human GAL-
hAR-(4–52) by Ala33 instead of Val33. VP-MAGE and
VP-MAGE-(112–429) interacted with GAL-hAR-(4–52), but
there was no interaction with GAL-mAR-(4–52) (Fig. 2C).
Direct in vitro binding between GST-hAR-(4–52) and
MAGE-11 was demonstrated previously (22).
When assayed using VP-hAR-(1–660) that contains human
ARNH2-terminal and DNA binding domains, the V33Amuta-
tion decreased the human AR N/C interaction and eliminated
the interactionwithMAGE-11 (Fig. 2D). Conversely, VP-mAR-
(2–640)-A33V with a substitution mutation to mimic human
AR interacted with GAL-MAGE and GAL-MAGE-(112–919)
and to a greater extentwithGAL-hAR-(658–919). Dependence
on the AR FXXLF motif was demonstrated by the inability of
VP-hAR-(1–660)-L26A,F27A to interact with GAL-AR-(658–
919), GAL-MAGE, or GAL-MAGE-(112–429).
Dependence of the AR N/C interaction on Val33 was investi-
gated further by expressing corresponding hAR-(1–503) and
FIGURE 1. Vertebrate evolution of AR FXXLF motif region and model of AR, MAGE-11, TIF2, and p300 interactions. A, human AR amino acid residues
16 –34 (Homo sapiens; GenBank accession no. P10275) are compared with corresponding AR regions from chimpanzee (Pan troglodytes; GenBank accession no.
NP001009012), crab-eating macaque (Macaca fascicularis; GenBank accession no. AAC73050), collared brown lemur (Eulemur fulvus collaris; GenBank accession
no. U94178), house mouse (Mus musculus; GenBank accession no. NP038504.1), Norway rat (Rattus norvegicus; GenBank accession no. NP036634), African
clawed frog (Xenopus laevis; GenBank accession no. NP001084353), goldfish (Carassius auratus; GenBank accession no. AAM09278), Japanese eel (Anguilla
japonica; GenBank accession no. BAA75464; AR-), and rainbow trout (Oncorhynchus mykiss; GenBank accession no. NP001117656; AR-). Highlighted in red
are FXXLF motif residues required for the AR N/C interaction or interaction with MAGE-11. B, human AR NH2-terminal FXXLF motif residues 23–33 (hydrophobic
residues underlined) precede AF1. High affinity androgen binding in the human AR ligand binding domain (LBD) initiates FXXLF motif binding to AF2 in the N/C
interaction and restricts p160 coactivator LXXLL motif binding to AF2. Val33 flanking the AR FXXLF motif in humans and other primates was required for the N/C
interaction inhibition of AF2 and a direct interaction with MAGE-11. AR in lower mammals such as rat and mouse has Ala33 instead of Val33. Ala33 was not
compatible with a direct interaction with MAGE-11. In agreement with MAGE family genome sequence analysis that MAGE-11 is primate-specific, MAGE-11 or
another FXXLF motif-interacting protein was not identified in a mouse testis expression library using the mouse AR FXXLF motif region as bait. A direct
interaction between human AR and MAGE-11 provides a primate-specific gain in function. MAGE-11 increases activity of other steroid hormone receptors in
an FXXLF motif-independent manner through interactions with receptor-associated p300 and p160 coactivators. DBD, DNA binding domain.
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mAR-(1–483) NH2-terminal fragments that lack the DNA and
ligand binding domains with the hAR-(507–919) DNA and
ligand binding domain fragment. Greatest androgen-depen-
dent andN/C interaction-dependent intermolecular activation
of the PSA enhancer resulted from hAR-(507–919) coex-
pressed with hAR-(1–503) or mAR-(1–483)-A33V; activation
was lower with hAR-(1–503)-V33A or mAR-(1–483) (Fig. 2E).
The androgen-dependent intermolecular interaction activa-
tion between these fragments was eliminated by L26A,F27A
mutations in the human and mouse AR FXXLF motif.
The results suggest that the evolutionary change from ala-
nine to valine at AR residue 33 in the primate lineage strength-
ens the androgen-dependent AR N/C interaction in primates.
The same transition mutation to Val33 also enables human AR
to interact directly with MAGE-11.
Greater Transcriptional Activity of Human AR—The ability
of MAGE-11 to increase human AR transcriptional activity
(22–24, 27) together with the inability of mouse AR to interact
with MAGE-11 (Fig. 2) and the apparent absence of MAGE-11
in mouse (see Fig. 6) suggested that MAGE-11 may contribute
to species-specific differences in AR transcriptional strength.
Transcriptional activities of human and mouse AR were com-
pared in HeLa cells that express endogenous MAGE-11 (Fig.
3A, top panel, lane 1) and in CV1 cells with low levels of
MAGE-11 mRNA (37) and no detectable MAGE-11 protein
(Fig. 3A, top panel, lane 2). Transcriptional activity was deter-
mined using the human PSA and rat probasin enhancer-lu-
ciferase reporter genes that depend on the AR N/C interaction
for maximal activation by human AR (7). In agreement with an
androgen-dependent N/C interaction for human and mouse
AR (Fig. 2), both receptors were stabilized in the presence of 10
nM DHT (Fig. 3A, lower panel) (21, 38).
Androgen-dependent human AR transactivation of PSA-
Enh-Luc (Fig. 3B) and probasin BH500-Luc (Fig. 3C) exceeded
FIGURE 2. Human, rat, and mouse AR FXXLF motif interaction with AR ligand binding domain and MAGE-11. A, GAL-hAR-(658 –919) (0.1 g) was
expressed in HeLa cells with 0.1 g of 5XGAL4Luc3 and 50 ng of VP16 empty vector (), human VP-hAR-(1– 660), mouse VP-mAR-(2– 640), or rat VP-rAR-(2– 643)
with and without 10 nM DHT. GAL-hAR-(658 –919) contains the human AR ligand binding domain sequence conserved in mouse and rat, except hAR Leu659
outside the hormone binding region is methionine in mouse and rat AR. B, GAL-MAGE and GAL-MAGE-(112– 429) (50 ng) were expressed in HeLa cells with 0.1
g of 5XGAL4Luc3 and 50 ng of VP16 empty vector (), VP-hAR-(1– 660), VP-mAR-(2– 640), or VP-rAR-(2– 643). Inset, VP16 empty vector (), VP-hAR-(1– 660),
VP-mAR-(2– 640), and VP-rAR-(2– 643) (5 g) were expressed in COS cells incubated with 1 M MG132 for 24 h prior to harvest. The transblot of cell extracts (80
g of protein/lane) was probed using VP16 antibody. C, GAL-hAR-(4 –52) and GAL-mAR-(4 –52) (50 ng) were expressed in HeLa cells with 0.1 g of 5XGAL4Luc3
and 50 ng of VP16 empty vector (), VP-MAGE, or VP-MAGE-(112– 429). Inset, GALO empty vector (), GAL-hAR-(4 –52) (H), or GAL-mAR-(4 –52) (M) (5 g) were
expressed in COS cells incubated with 1 M MG132 for 24 h prior to harvest. The blot was probed using GAL4 antibody. D, GAL-hAR-(658 –919) (0.1 g),
GAL-MAGE (50 ng), or GAL-MAGE-(112– 429) (50 ng) was expressed in HeLa cells with 0.1 g of 5XGAL4Luc3 and 50 ng of VP16 empty vector (), VP-hAR-(1–
660) wild type (WT) or L26A,F27A (LFAA) or V33A (VA33) mutant, or VP-mAR-(2– 640) WT or A33V (AV33) or L26A,F27A mutant. Inset, VP16 empty vector (),
VP-hAR-(1– 660) WT and V33A and L26A,F27A (LFAA) mutants, and VP-mAR-(2– 640) WT and A33V and L26A,F27A mutants (10 g) were expressed in COS cells
and incubated for 24 h with 1 M MG132 prior to harvest. The transblot of cell extracts (60 g of protein/lane) was probed using VP16 antibody. E, pCMV-hAR-
(507–919) (50 ng) and PSA-Enh-Luc (0.1 g) were transfected in HeLa cells with 50 ng of pCMV5 empty vector (), pCMV-hAR-(1–503) WT or V33A or L26A,F27A
(LFAA) mutant, or pCMV-mAR-(1– 483) WT or A33V or L26A,F27A mutant. Cells were incubated with and without 10 nM DHT. Inset, pCMV5 empty vector (),
pCMV-hAR-(1–503) WT and V33A and L26A,F27A (LFAA) mutants, and pCMV-mAR-(1– 483) WT and A33V and L26A,F27A mutants (5 g) were expressed in COS
cells. Cell extracts (20 g of protein/lane) were analyzed on the transblot using AR32 antibody.
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that of mouse AR in HeLa cells in the presence of 0.1 nM DHT.
The activity of human andmouse AR F26A,F27A FXXLFmotif
mutants decreased to the greatest extent at the lower concen-
trations of DHT. It was noteworthy that the transcriptional
strength of hAR-L26A,F27A in which the FXXLFmotif binding
site forMAGE-11was disruptedwas similar to that of wild-type
mouse AR (Fig. 3, B and C). In CV1 cells that essentially lack
MAGE-11 (Fig. 3A), human and mouse AR transactivation of
PSA was similar and FXXLF motif-dependent (Fig. 3D).
The results suggest that maximal human and mouse AR
transactivation requires the AR N/C interaction. The greater
transcriptional strength of human AR relative to mouse in cells
expressing MAGE-11 was consistent with the coactivator
effects of MAGE-11 interaction with the human AR FXXLF
motif region.
Requirement for MAGE-11 in Human AR Transcriptional
Activity—Lentiviruses expressing MAGE-11 shRNAs were
tested for their ability to silence MAGE-11 expression. Maxi-
mal inhibition of MAGE-11 protein expression was seen with
MAGE-11 shRNA-947 in HeLa cells that stably express AR
(Fig. 4A, lanes 7 and 8). MAGE-11 shRNA-947 was also more
effective in inhibiting HeLa-AR cell growth (Fig. 4B). AR pro-
tein expression was reduced using lentivirus AR shRNA-5 (Fig.
4A, lanes 11 and 12).
The requirement for MAGE-11 in androgen-dependent
humanAR transactivationwas investigated by quantitative RT-
PCR of endogenous PSA in LAPC-4 prostate cancer cells that
haveMAGE-11mRNA levels10-fold greater thanHeLa cells,
100-fold greater than Ishikawa human endometrial cancer
cells, and1000-fold greater than normal human prostate cells
(37). As seen with the HeLa-AR cells (Fig. 4), lentivirus AR
shRNA-5 and MAGE-11 shRNA-947 were most effective in
silencing AR and MAGE-11 expression in LAPC-4 cells,
respectively, based on immunoblot (Fig. 5A, lanes 4 and 6) and
RT-PCR analyses of MAGE-11 mRNA (Fig. 5B). Human AR
shRNA-5 and MAGE-11 shRNA-947 decreased androgen-de-
pendent humanAR transactivation of PSA to an extent not seen
with the partial silencing of MAGE-11 (Fig. 5C). Specificity of
inhibition was suggested by androgen-dependent up-regula-
tion of PSAwithout lentivirus orwith control lentivirus that did
not alter AR or MAGE-11 levels (Fig. 5, A–C). MAGE-11
FIGURE 3. Comparison of human and mouse AR transcriptional activity.
A, top panel, immunoblot of endogenous MAGE-11 in HeLa (HL; lane 1) and
CV1 (CV; lane 2) cell extracts (120 g of protein/lane) was probed using
MAGE-11 and -actin antibodies. A cell extract (0.2 g of protein) of COS cells
expressing pSG5-MAGE served as control (lane 3). Bottom panel, immunoblot
of extracts (40 g of protein/lane) from COS cells transfected with 5 g of
pCMV5 empty vector (), pCMV-hAR, pCMV-mAR, and L26A,F27A mutants
(LFAA). Cells were incubated for 24 h with and without 10 nM DHT. The trans-
blot was probed using AR32 antibody that recognizes the same NH2-terminal
epitope in human and mouse AR. B, pCMV-hAR, pCMV-mAR, and L26A,F27A
mutants (10 ng) were transfected with 0.25 g of PSA-Enh-Luc in HeLa cells
incubated with and without 0.01 or 0.1 nM DHT. C, pCMV-hAR, pCMV-mAR,
and L26A,F27A mutants were transfected with 0.25 g of BH500-Luc rat pro-
basin reporter in HeLa cells incubated for 24 h with and without 0.1 nM DHT.
D, pCMV-hAR, pCMV-mAR, and L26A,F27A mutants (0.1 g) were transfected
with 5 g of PSA-Enh-Luc in CV1 cells with and without 1 nM DHT.
FIGURE 4. Silencing MAGE-11 slows growth of HeLa cells stably expressing AR. A, HeLa-AR1C-PSA-Luc-6A cells stably expressing AR were not treated with
lentivirus (lane 1 and 2) or transduced with lentivirus MAGE-11 shRNA-169, -827, -947, and -964 (lanes 3–10); human AR shRNA-5 (lanes 11–12); empty vector
(NS-1; lanes 13 and 14); or 18-bp-spacer nonspecific shRNA (NS-2; lanes 15 and 16). After puromycin selection, cells were incubated for 24 h with and without 10
nM DHT. Cell extracts (65 g of protein/lane) were separated on SDS gels. Transblots were probed using AR32 and AR52 antibodies combined; MAGE-Ab-59 –
79, MAGE-Ab-94 –108, and FLAG-MAGE-11 antibodies combined; and -actin antibody. Extracts from COS cells expressing pSG5-MAGE (5 g of protein; lane
17) served as control. B, HeLa-AR1C-PSA-Luc-A6 cells were incubated with lentivirus as described in A. After puromycin selection, cell growth assays were
performed over several days as described under “Experimental Procedures.” The data are the mean of triplicate measurements.
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shRNA-947 did not alter AR protein levels (Fig. 5A, lane 4), but
knockdown of AR decreased MAGE-11 mRNA (Fig. 5B). In
agreementwith the low levels ofMAGE-11 inmost cells and the
requirement for maximal silencing of MAGE-11 to inhibit AR
activity, the results suggest that MAGE-11 is a low abundance
but essential human AR coregulator.
Absence of MAGE-11 Homologue in Mice—To determine
whether less evolved mammals express MAGE-11 or a related
protein that interacts with the AR FXXLF motif, genome-wide
sequence comparisons (Fig. 6) and two-hybrid screens were
performed. Comparison of human, Rhesus macaque (Macaca
mulatta), mouse, and rat MAGE gene families suggests diver-
gent evolution between the lower mammals and primates (Fig.
6, A–D). The 429-amino acid human and Rhesus macaque
MAGE-11 proteins represented by the top black bar (Fig. 6, A
and B) were absent in the mouse and rat genomes (Fig. 6,C and
D). Human and Rhesus macaque MAGE-11 have 93% amino
acid sequence homology with shared regions important for
coregulator function. Conserved functional domains include
nuclear localization residues 18–23, Ser174 mitogen-activated
protein kinase phosphorylation site, 185MXXIF189 interaction
motif for p300, Lys240 and Lys245 monoubiquitinylation sites
required to bind the human AR FXXLF motif, 260FPEIF264
FXXIF interaction motif for TIF2, and Thr360 Chk1 cell cycle
checkpoint kinase phosphorylation site in the F-box-like 329–
369 residues that bind the human AR FXXLF motif (23, 24, 27)
(Fig. 6E, highlighted in red). The 7% sequence divergence
between human and Rhesus macaque MAGE-11 outside these
functional domains is consistent with continuing evolution of
the MAGE gene family in primates.
With MAGE-11 absent in the mouse and rat genomes, there
remained the possibility of a related AR FXXLF motif-interact-
ing protein in mouse. This idea gained some support from the
extensive sequence conservation in the MAGE homology
domain region that interacts with the human AR FXXLFmotif.
Yeast two-hybrid screens were performed using a mouse testis
library. Mouse GAL-mAR-(4–52) bait vector contained Ala33
instead of Val33 in GAL-hAR-(4–52) used to identify
MAGE-11 in a human testis library (22). A secondmouse testis
library screen was performed using GAL-mAR-(2–285) that
contained additional mouse AR NH2-terminal sequence.
None of the 28 positive mouse AR-interacting proteins were
FXXLF motif-dependent or recapitulated the transcription
enhancing effects of MAGE-11 seen with human AR. Results
from MAGE gene family comparisons and two-hybrid screens
provide evidence that the coregulator function of MAGE-11 is
primate-specific.
Transcriptional Synergy betweenMAGE-11 and Receptor-as-
sociated p300 and p160 Coactivators—MAGE-11 binds TIF2, a
coactivator that interacts with AF2 in the AR ligand binding
domain, and p300 (23, 24), an acetyltransferase that interacts
with theNH2-terminal region ofARandother steroid receptors
(39) (Fig. 1B). This raised the possibility that MAGE-11 has
transcriptional effects independent of binding an FXXLF motif
by interacting with receptor-associated coactivators. Initial
support for this came from the coimmunoprecipitation of
FLAG-MAGE in a complex with human and mouse AR (Fig.
7A), human GR (Fig. 7B), and human PR-B (Fig. 7C) expressed
in cells treated with receptor agonists and EGF. The experi-
mental conditions were similar to the optimal interaction condi-
tions for nuclear and cytoplasmic MAGE-11 interaction with
liganded and unliganded human AR, respectively (22, 27).
MAGE-11 also increased the transcriptional activity ofmouse AR
and the L26A,F27A FXXLF motif mutant and was most effective
with mAR-A33V (Fig. 8A). The hAR-L26A,F27A FXXLF motif
mutation that disrupts the N/C interaction decreased activity,
whereas hAR-V33Awith anN/C interaction retained activity that
increased with MAGE-11. MAGE-11 functioned synergistically
withTIF2 andmouseAR (Fig. 8B) and increasedhumanPR-B and
GR activity with TIF2 and p300 (Fig. 8,C andD).
Because the transcriptional effects of TIF2 are mediated pre-
dominantly by LXXLLmotif binding to AF2 in the ligand bind-
ing domain (21, 36), the effects of MAGE-11 and TIF2 were
evaluated further using correspondingDNAand ligand binding
domain regions of mouse and human AR, human PR, and rat
GR. Deletion of the NH2-terminal region in hAR-(507–919)
(Fig. 9A) removed the inhibitory effect of the AR N/C interac-
tion on AF2 activation by TIF2 (21). MAGE-11 itself had little
effect on the transcriptional activity of hAR-(507–919), mAR-
(487–899), rGR-(399–795), or hPR-B-(486–933) (Fig. 9B). In
contrast, TIF2 increased the activity of each of these fragments
and functioned synergistically withMAGE-11. The decrease in
activity of hAR-(507–919)-K720A and the corresponding
mAR-(487–899)-K700A charge clampmutant demonstrated a
dependence on TIF2 binding to AF2 (14, 40).
Synergistic effects of MAGE-11 and p300 in activating the
PSA-enhancer-luciferase reporter gene were analyzed using
humanAR-(1–660) (Fig. 9A) and correspondingNH2-terminal
FIGURE 5. Requirement for MAGE-11 in human AR transactivation. A, LAPC-4 cells were untreated (lane 1) or transduced with lentivirus MAGE-11 shRNA-
169, -827, -947, and -964 (lanes 2–5); human AR shRNA-5 (lane 6); empty vector (NS1; lane 7); or 18-bp-spacer nonspecific shRNA (NS2; lane 8). Cell extracts (100
g of protein/lane) separated on transblots were probed using AR32 and AR52 antibodies combined, MAGE-Ab-94 –108 and FLAG-MAGE-11 antibodies
combined, and -actin antibody. B, quantitative real time RT-PCR analysis of MAGE-11 mRNA from LAPC-4 cells was performed as described under “Experi-
mental Procedures” using cells not treated with lentivirus () or transduced with lentivirus MAGE-11 shRNA-169, -827, -947, and -964 (M); human AR shRNA-5
(AR); and 18-bp nonspecific shRNA-2 (NS). Cells were incubated for 24 h with 10 nM DHT. MAGE-11 mRNA levels were normalized to peptidylprolyl isomerase
A (PPIA) mRNA. C, quantitative real time RT-PCR analysis of PSA mRNA was performed in LAPC-4 cells as in B except that cells were incubated for 24 h with and without
10 nM DHT. Results indicate PSA mRNA -fold induction normalized to peptidylprolyl isomerase A assayed in triplicate S.E. relative to activity without DHT.
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and DNA binding regions of mouse AR and human PR-B and
GR that lack the ligand binding domain. Studies were per-
formed in CV1 cells that have 2–3-fold less endogenous p300
than HeLa cells (Fig. 9C, top panel) and in HeLa cells to assess
the effects of silencing p300 (Fig. 9, E and F). MAGE-11 and
p300 synergistically increased the activity of hAR-(1–660),
mAR-(1–640), hPR-B-(1–688), and hGR-(1–550) (Fig. 9D).
A requirement for endogenous p300 was demonstrated with
hAR-(1–660) expressed in HeLa cells and p300 siRNA-1, -3,
and -4 (Fig. 9E) that reduced p300 levels (Fig. 9C, lower
panel). p300 siRNAs also inhibited transcriptional activity of
the androgen-dependent intermolecular ARN/C interaction
between hAR-(507–919) and hAR-(1–503) (Fig. 9, A and F)
(24). Specificity of inhibition was suggested by persistent
activation in the presence of nonspecific siRNA or p300
siRNA-2 that did not silence p300 (Fig. 9, E and F). The
results suggest that MAGE-11 can increase steroid receptor
transcriptional activity also by an FXXLF motif-independent
mechanism through its interaction with receptor-associated
TIF2 and p300.
HumanandMouseARAF2Activity—The inhibitory effect of
the human AR N/C interaction on AF2 activity can be relieved
either by mutating the AR FXXLF motif to FXXAA or by
MAGE-11 binding to the humanAR FXXLFmotif (21, 23). The
inability of mouse AR to interact directly withMAGE-11 raised
the possibility thatmouse ARAF2 activitymay be inhibited to a
greater extent than human AR by the N/C interaction. On the
other hand, a weaker mouse AR N/C interaction (Figs. 2E and
8A) may not inhibit AF2 activity. To test this further, the effect
of the AR N/C interaction on human and mouse AR AF2 acti-
vation by TIF2 was investigated using hAR120–472, an AF1
deletion mutant (Fig. 9A) that depends on AF2 for transcrip-
tional activity (23), and the corresponding mAR101–452
mouse mutant.
FIGURE 6. Human, Rhesus macaque, mouse, and rat MAGE gene families and human and macaque MAGE-11 sequence alignment. Shown are schematic
diagrams of NCBI BLAST Assembled RefSeq results comparing the human MAGE-11 amino acid sequence with the MAGE gene family of human (A), Rhesus
macaque (B), mouse (C), and rat (D) where the top black bar represents MAGE-11 in human and macaque absent in mouse and rat. E, amino acid sequence
alignment of human (GenBank accession no. NP-005357) and M. mulatta Rhesus monkey MAGE-11 (GenBank accession no. XM-001090027) indicates 93%
homology. Highlighted in red are conserved regions reported for nuclear targeting residues 18 –23, mitogen-activated protein kinase phosphorylation site
Ser174, 185MXXIF189 interaction site for p300, Lys240 and Lys245 monoubiquitinylation sites, 260FPEIF264 interaction site for TIF2, F-box-like residues 329 –369 that
bind the human AR FXXLF motif, and cell cycle checkpoint kinase Chk1 phosphorylation site Thr360 in the F-box (22–24, 27).
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In agreement with previous studies (23), transactivation of
MMTV-Luc by hAR120–472 required the expression of both
TIF2 and MAGE-11 (Fig. 10A). The inhibitory effect of the
human AR N/C interaction on AF2 activity that was overcome
by MAGE-11 was also indicated by TIF2 activation of the
hAR120–472-L26A,F27A FXXLF motif mutant in the
absence ofMAGE-11. Dependence onTIF2 LXXLLmotif bind-
ing to AF2 was shown by loss of transcriptional activity by the
K720A charge clamp mutant. However, hAR120–472-V33A
in which Val33 was changed to Ala33 to mimic mouse AR was
inactivewith andwithoutTIF2 orMAGE-11. This suggests that
the human AR N/C interaction inhibition of AF2 activity in
hAR120–472-V33A could not be rescued by MAGE-11 con-
sistent with the requirement for AR Val33 to interact directly
with MAGE-11.
In contrast, the corresponding mouse mAR101–452 and
L26A,F27A FXXLF motif mutants were strongly activated by
TIF2 with or without the expression of MAGE-11 (Fig. 10B).
When Ala33 was changed to Val33 in mAR101–452-A33V to
mimic human AR, transcriptional activity required TIF2 and
MAGE-11. Partial retention of activity by the mAR101–452-
K700A charge clamp mutant suggested that mouse AR may be
activated to some extent by TIF2 outside the mouse AR AF2
site. However, similar to human AR, transcriptional activity was
lost by combiningmutations in mAR101–452-A33V,K700A.
We noted that hAR120–472 migrated as a double band on
immunoblots, whereas mAR101–452 was a single band (Fig.
10, A and B, top insets). In agreement with previous studies
showing that humanAR is phosphorylated on Ser94 (41, 42), the
hAR120–472-S94Amutant migrated as a single band similar
to wild-type mouse AR. However, the inhibitory effect of the
human AR N/C interaction on AF2 activity not seen with
mouse AR could not be attributed to differences in Ser94 phos-
phorylation. Human AR and mouse AR share the same NH2-
terminal EDGSPQAH sequence that contains human AR
Ser94,Pro95 (underlined), which is Ser74,Pro75 in mouse AR.
Human AR Ser94 is shifted in position relative to mouse AR by
glutamine repeat residues 58–78 (5). In addition, hAR120–
472-S94A required MAGE-11 for AF2 activation by TIF2 sim-
ilar to hAR120–472 (Fig. 10A). When the glutamine repeat
length of hAR120–472 was reduced from 24 to 5 residues to
mimicmouseAR, the double bandmigrationwas lost (Fig. 10A,
bottom inset), but TIF2 andMAGE-11 were required for trans-
activation (data not shown).
The results suggest fundamental differences in the regulation
of human and mouse AR transcriptional activity. Val33 in
FIGURE 7. Coimmunoprecipitation of FLAG-MAGE-11 with human AR,
mouse AR, human PR-B, and human GR. COS cells were transfected with 3
g of FLAG empty vector or FLAG-MAGE and 1 g of pCMV-hAR or 2 g of
pCMV-mAR in cells incubated with and without 10 nM DHT (A), 2 g of pCMV-
hGR in cells incubated with and without 10 nM dexamethasone (DEX; B), and 2
g of p5M-hPR-B in cells incubated with and without 10 nM progesterone
(PROG; C), all in the presence of 0.1 M EGF. Cell extracts (50 g of protein/
lane) and immunoprecipitated proteins (IP) were analyzed by immunoblot
using AR, GR, and PR antibodies.
FIGURE 8. MAGE-11 increases steroid receptor transcriptional activity. A, pCMV-hAR WT and L26A,F27A (LFAA) and V33A (VA33) mutants and pCMV-mAR
WT and L26A,F27A and A33V (AV33) mutants (10 ng) were transfected with 25 ng of pSG5 empty vector () or 25 ng of pSG5-MAGE (M) and 0.25 g of
PSA-Enh-Luc in HeLa cells. Cells were incubated in the absence and presence of 0.1 nM DHT. (Inset) pCMV5 empty vector (), wild-type pCMV-hAR (WT hAR),
L26A,F27A (LFAA), and V33A mutants, and pCMV-mAR (WT mAR), L26A,F27A, and A33V mutants (5 g) were expressed in COS cells. The transblot of cell
extracts (40 g protein/lane) was probed using AR32 antibody. B, pCMV-hAR and pCMV-mAR (0.1 g) were transfected in CV1 cells with 1.5 g of pSG5 empty
vector (), 0.5 g of pSG5-MAGE, and/or 2 g of pSG5-TIF2 and 3 g of PSA-Enh-Luc. Cells were incubated in the absence and presence of 1 nM DHT.
C, p5M-hPR-B (0.1 g) and PSA-Enh-Luc (2.5 g) were transfected in CV1 cells with and without 1.5 g of pSG5 (), 1.5 g of pSG5-TIF2 (T), 0.5 g of pSG5-MAGE
(M), and 1.5 g of pSG5-HA-p300 (P). Cells were incubated in the absence and presence of 1 nM progesterone (Prog). D, pCMV-hGR (0.1 g) and PSA-Enh-Luc
(2.5 g) were transfected as in C with cells incubated in the absence and presence of 10 nM dexamethasone (Dex).
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human AR resulted in a stronger N/C interaction and inhibi-
tion of AF2 that was released by the competitive binding of
MAGE-11. Ala33 in mouse AR caused a weaker AR N/C inter-
action that did not require MAGE-11 for AF2 activity in an
animal model that does not express MAGE-11.
DISUCSSION
Convergent Evolution of AR NH2-terminal Sequence and
MAGE-11—Our findings suggest species-specific differences
in AR transactivation mediated by the effects of the AR N/C
interaction and MAGE-11. The androgen-dependent AR N/C
FIGURE 9. Steroid receptor synergism with MAGE-11, TIF2, and p300. A, full-length human AR amino acid residues 1–919 and hAR-(1– 660), -(1–503),
-(507–919), and 120 – 472 deletion mutants contain the NH2-terminal
23FXXLFXXVXXV33 motif, AF1, DNA binding domain (DBD), and AF2 in the ligand binding
domain (LBD) as indicated. Human AR-(1– 660) corresponds to mAR-(1– 640), hPR-B-(1– 688), and hGR-(1–550). Human AR-(507–919) corresponds to mAR-
(487– 899), rGR-(399 –795) and hPR-B-(486 –933). Human AR120 – 472 corresponds to mAR101– 452. B, pCMV-hAR-(507–919) WT or K720A mutant, corre-
sponding pCMV-mAR-(487– 899) and K700A mutant, pCMV-rGR-(399 –795), and pcDNA-myc-PR-B-(486 –933) (0.1 g) were transfected with 3 g of MMTV-Luc
and 0.5 g of pSG5 empty vector (), pSG5-MAGE (M), and/or pSG5-TIF2 (T) in CV1 cells. Cells were incubated with and without 10 nM DHT for AR, 10 nM
dexamethasone for GR, and 10 nM progesterone for PR. Inset, pCMV5 empty vector (), pCMV-hAR-(507–919) and K720A mutant, and corresponding pCMV-
mAR-(487– 899) and K700A mutant (5 g) were expressed in COS cells. The transblot of cell extracts (50 g of protein/lane) was probed using AR52 antibody.
C, top panel, endogenous protein extracts (100 g/lane) from HeLa (HL; lane 2) and CV1 (CV; lane 3) cells were compared with extracts of COS cells expressing
pSG5-HA-p300 and pSG5-TIF2 as control (10 g of protein; lane 1). The blot was probed using p300, TIF2, and -actin antibodies. Bottom panel, pSG5 empty
vector (lane 1) and pSG5-HA-p300 (lanes 2–9) (2 g) were expressed in COS cells with and without 10 nM nonspecific siRNA-3 (NS3), -5 (NS5), or p300-siRNA-1– 4
using Lipofectamine 2000. Cell extracts (15 g of protein/lane) on the transblot were probed overnight at 4 °C using p300 and -actin antibodies. D, CV1 cells
were transfected with 3 g of PSA-Enh-Luc and 10 ng of human pCMV-hAR-(1– 660), pCMV-mAR-(1– 640), p5M-hPR-B-(1– 688), or pCMV-hGR-(1–550) with and
without 1.5 g of pSG5 (p5) empty vector (), 0.5 g of pSG5-MAGE (M), and 1 g of pSG5-HA-p300 (P). E, pCMV-hAR-(1– 660) (25 ng) was transfected into HeLa
cells using Lipofectamine 2000 without siRNA () or with 10 nM p300 siRNA-1– 4, nonspecific siRNA-3 (NS), and 0.1 g of PSA-Enh-Luc. F, pCMV-hAR-(507–919)
(50 ng) and pCMV-hAR-(1–503) (25 ng) were transfected in HeLa cells with 0.1 g of PSA-Enh-Luc as above except with 5 nM p300 siRNAs and nonspecific
siRNA-5 (NS5). Cells were incubated with and without 10 nM DHT.
FIGURE 10. Species differences in AR N/C interaction inhibition of AF2. A, CV1 cells were transfected with 3 g of MMTV-Luc and 0.1 g of human
pCMV-hAR120 – 472 WT or L26A,F27A (LFAA), S94A (SA94), V33A (VA33), or K720A (KA720) mutant with 1.5 g of pSG5 empty vector () and 2 g of pSG5-TIF2
(T) with and without 1 g of pSG5-MAGE (M). Cells were incubated in the absence and presence of 1 nM DHT. Inset, upper panel, pCMV5 empty vector (p5) ()
and pCMV-hAR120 – 472 WT and L26A,F27A, V33A, K720A, and S94A mutants (5 g) were expressed in COS cells in the presence of 10 nM DHT. Lower panel,
pCMV5 empty vector (); pCMV-hAR120 – 472 WT, Q5, and S94A; and pCMV-mAR101– 452 (5 g) were expressed in COS cells. Cell extracts (60 g of
protein/lane) were analyzed by immunoblot using AR32 antibody. B, CV1 cells were transfected with 3 g of MMTV-Luc and 0.1 g of corresponding WT mouse
pCMV-mAR101– 452 or L26A,F27A, A33V, K700A, or A33V,K700A mutants with 1.5 g of pSG5 empty vector () and 2 g of pSG5-TIF2 (T) with or without 1
g of pSG5-MAGE (M). Cells were incubated in the absence and presence of 1 nM DHT. Inset, pCMV5 empty vector (p5) () or pCMV-mAR101– 452 WT,
L26A,F27A, A33V (AV33), K700A (KA700), and A33V,K700A mutants (5 g) were expressed in COS cells incubated with 10 nM DHT. Cell extracts (50 g of
protein/lane) were analyzed by immunoblot using AR32 antibody.
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interaction between the NH2-terminal FXXLF motif and AF2
hydrophobic binding surface of the ligand binding domain
appears to occur in all mammals although to a greater extent in
primates due to the evolutionary transition mutation from AR
Ala33 to Val33. Evidence for the androgen-dependent AR N/C
interaction among all mammals was supported by androgen-
dependent stabilization of human and mouse AR, an interac-
tion that slows the dissociation rate of bound androgen from
human AR (6, 10). Previous studies confirmed a rat AR N/C
interaction that increased activity in associationwith transcrip-
tional effects of p160 coactivators (43). However, the evolution-
ary change from alanine to valine at residue 33 flanking the
23FQNLF27 motif in a predicted extended -helical region not
only strengthens the N/C interaction in primates but enables
human AR to interact directly with MAGE-11, a coregulator
that coevolved in the primate lineage. Studies using AR AF1
deletion mutants that depend on AF2 for activity showed that
human AR Val33 contributes to the inhibitory effect of the
human AR N/C interaction on AF2 activation by TIF2 that is
relieved by MAGE-11.
Convergent evolution of the AR NH2-terminal FXXLF motif
flanking sequencewith the expression ofMAGE-11 in primates
together with the ability of MAGE-11 to increase human AR
transcriptional activity and the dual functions of the humanAR
FXXLF motif compared with mouse AR suggests that human
and nonhuman primates have acquired increased regulatory
control over AR activation domains in association with a pri-
mate-specific gain in function (Fig. 11). Our previously pro-
posed model for an evolutionary transition from AF2 to AF1
among different steroid hormone receptors (36) appears to
apply also to the evolution ofmammalianARwhere primateAR
acquired the ability to regulate AF2 activity. The functional
importance of MAGE-11 in human AR transactivation of
androgen-responsive genes was supported by the effects of len-
tivirus shRNA silencing MAGE-11. The results suggest that
primates evolved increased regulatory control over AR activa-
tion domain usage to increase transcriptional strength.
Species-specific AR Function—Complete amino acid se-
quence conservation in the AR DNA and ligand binding
domains throughout mammalian evolution preserves the
structural constraints necessary for high affinity androgen and
DNAbinding. In contrast is the unstructuredARNH2-terminal
region, which is also important for AR function but less well
conserved. Human and mouse AR NH2-terminal regions share
84% amino acid sequence homology with the most highly
conserved regions at human AR amino acid residues 1–53,
234–247, and 360–429 (1, 35). Human AR residues 1–53 con-
tain the FXXLF motif that mediates the N/C interaction (6, 10)
and serves as the binding site for MAGE-11 (22). This region
precedes the polymorphic glutamine repeat that expanded dur-
ing primate evolution to an average length of 20–22 residues
(1). Human AR glutamine repeat residues 58–78 are shifted in
mouse AR to residues 174–193 (1, 5, 25). Expansion to more
than 39-glutamine repeat length in human AR causes spinal
bulbar muscular atrophy or Kennedy disease, an adult onset
muscle wasting disease associated with an AR gain in function
that requires theN/C interaction (4, 44).HumanARamino acid
residues 234–247 are within the binding region for CHIP (car-
boxyl terminus of the Hsp70-interacting protein), an E3 ubiq-
uitin ligase that targets AR for degradation (35). Human AR
residues 360–429 were implicated in transactivation (45).
Amino acid sequence conservation in the AR DNA binding
domain throughout evolution suggests that interaction sites in
chromatinmay be shared acrossmammalian species. However,
recent studies have shown surprisingly low sequence conserva-
tion for themajority ofmammalianARDNAbinding sites asso-
ciated with androgen-regulated genes (46). This suggests that
species-specific differences in AR gene regulation may be
attributed to differences in coregulatory proteins such as
MAGE-11.
Genome-wide sequence analysis and two-hybrid screens
showed that the AR coregulator function of MAGE-11 is pri-
mate-specific. This is consistent with differences in the rat and
mouse AR FXXLF motif flanking sequence where Ala33 in
mouse AR is not compatible with direct binding to MAGE-11.
However, absence of an FXXLF motif that binds MAGE-11 in
mouse AR or other steroid receptors did not rule out transcrip-
tional effects.MAGE-11 coexpressedwithmouseAR or human
PR-B or GR was present in a complex presumably through its
interactionwith p300 and p160 coactivators. In agreementwith
this, MAGE-11 increased steroid receptor transcriptional
activity also by an FXXLF motif-independent mechanism. Evi-
dence that MAGE-11 can increase steroid receptor activity
through an association with p300 and p160 coactivators broad-
FIGURE 11. Model of MAGE-11 interaction with steroid receptors.
MAGE-11 F-box residues interact with the extended human AR FXXLFXXVXXV
motif sequence 23FQNLFQSVREV33 that ends with Val33. Both hAR and mAR
undergo the androgen-dependent N/C interaction. However, human AR
Val33 that is Ala33 in mouse AR is required for a direct interaction with
MAGE-11 and for the AR N/C interaction inhibition of AF2 activity that is
relieved by MAGE-11. MAGE-11 MXXIF motif interaction with p300 (24)
enhances transcriptional activity from the NH2-teminal regions of human AR,
PR-B, and GR. MAGE-11 FXXIF motif interaction with p160 coactivators (23)
enhances AF2 activity from the human AR, PR-B, and GR carboxyl-terminal
ligand binding domains (LBD). Although mouse AR is activated by p300 and
p160 coactivators, MAGE-11 is not present in mouse, and the mouse AR NH2-
terminal FXXLFXXVXXA motif sequence would not interact directly with
MAGE-11. Human and nonhuman primate AR transcriptional activity is regu-
lated by the primate-specific coevolution of MAGE-11 and the AR NH2-termi-
nal FXXLFXXVXXV interaction site for MAGE-11. DBD, DNA binding domain.
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ens its potential impact in human reproductive physiology.
MAGE-11 interaction with receptor-associated p300 and p160
coactivators may have been the evolutionary progenitor for the
primate-specific direct interaction with human AR (Fig. 11).
Species-specific differences in AR activity have been re-
ported previously. Rat AR activation of MMTV-chloramphen-
icol acetyltransferase reporter gene in CV1 cells was less than
that of human AR with differences attributed to the AR NH2-
terminal region (47). However, we did not detect MAGE-11
protein in CV1 cells, and mRNA levels were low (37). This sug-
gests that additional mechanisms involving the NH2-terminal
region increase human AR transcriptional strength. Attempts
to mimic human AR in a humanized mouse model made use of
a human AR NH2-terminal region 5 SmaI site fragment that
begins at human AR amino acid residue 37 so that the chimera
retained mouse Ala33 (48). Even with the absence of MAGE-11
in mouse, the unregulated p160 coactivator access to AF2 that
characterizesmouseARwould be expected to be retained in the
presence of AR Ala33.
CpG dinucleotides are hot spots for mutation that account
for approximately one-third of disease-causing germ linemuta-
tions (49, 50) and a significant proportion of human AR muta-
tions that cause the androgen insensitivity syndrome (51). CpG
dinucleotides can become methylated, and 5-methylcytosine
can undergo spontaneous deamination that results in a C3T
transitionmutation in genomicDNA.Our findings suggest that
mutations at CpG dinucleotides also contribute to the evolu-
tion of new gene sequences. Ala33 inmouse and rat AR is coded
by GCG, which in primates changed to GTG coding for Val33.
Rat andmouseARGCGcodon33 is followedbyA in the sequence
GCGA, and CGAwas preferentially associated with mutations in
the retinoblastoma gene (50). Methylation and deamination of
CpG in AR codon 33 in the less evolved mammals may have
caused the evolutionary transition fromAla33 to Val33 needed for
the ARN/C interaction inhibition of AF2 activity and the binding
to MAGE-11 that releases that inhibition in primates. MAGE-11
may have evolved to regulateAR transcriptional activity in part by
relieving the inhibitory effects of the AR N/C interaction associ-
ated with the ARAla33 to Val33 mutation.
Species-specific MAGE Gene Families—The rapid evolution
of the MAGE gene family among mammals results from gene
duplication and retrotransposition (52). TheMAGE-11 gene is
part of a MAGE-A subfamily expressed at Xq28 on the human
X chromosome and contains three short unique 5 coding
exons that precede a major, more highly conserved 3 coding
exon (22, 53). A two-hybrid interaction screen of a human testis
library using the human AR FXXLF motif region as bait identi-
fiedMAGE-11 as a humanAR coregulator (22). A similar screen
of a mouse testis library using the corresponding mouse AR
FXXLFmotif region as bait suggested the absence of a related AR
FXXLFmotif-interacting protein inmouse. This finding was con-
sistent with genome-wide sequence analysis ofMAGE gene fami-
lies that no other mouse MAGE family protein corresponds to
human MAGE-11. It was also consistent with the absence of an
inhibitory effect of themouseARN/C interaction onAF2 activity.
The results support the absenceofMAGE-11 inmammals outside
theprimate lineageandaprimate-specificARgain in function that
increases transcriptional strength of AR and other steroid hor-
mone receptors. The absence of MAGE-11 in lower mammals
suggests its coevolution with the AR FXXLF motif flanking
sequence and increased regulatory control of AR activation
domain dominance through evolution.
The ability of MAGE-11 to increase human AR transcrip-
tional activity places it among a growing list of AR coactivators
(54). However, the precise mechanisms that underlie its
coregulator function remain to be established. MAGE-11 is a
multifunctional protein that interacts with p300 and p160
coactivators (23, 24) and undergoes post-translational modifi-
cation that includes phosphorylation by mitogen-activated
protein kinase and cell cycle checkpoint kinase Chk1 and
monoubiquitinylation at lysine residues required to interact
with the human AR FXXLFmotif (23, 27). A role forMAGE-11
in androgen-dependent cell cycle regulation is suggested by a
number of MAGE family proteins that influence cell cycle pro-
gression and apoptosis in humans (55). A MAGE-A subfamily
binding partner is a RING E3 ubiquitin ligase whose activity
increases in association with MAGE proteins (56). Some
MAGE-Aproteins inhibit p53 tumor suppressor activity during
tumor development (57). MAGE-11 was shown to be an inter-
action partner and inhibitor of the major hypoxia-inducible
factor HIF-1-hydroxylating enzyme prolyl hydroxylase 2 and
stabilizes HIF-1 in a potential tumor-associated regulatory
mechanism (58). It remains to be established whether these
functions are important for MAGE-11 activity as a steroid
receptor coregulator.
The ability of MAGE-11 to increase transcriptional strength
of human AR through a direct interaction with the AR FXXLF
motif has important implications in normal human reproduc-
tive physiology and cancer. MAGE-11 mRNA levels increase
more than 50-fold in themid-secretory glandular epithelium of
human endometrium during the window of receptivity for
implantation, suggesting a role in human embryo implantation
or survival (34). MAGE-11 mRNA levels are acutely up-regu-
lated by cyclic AMP, a second messenger signaling response to
the preovulatory luteinizing hormone surge. However, the
physiological effects of AR and MAGE-11 in human endome-
trium during the window of implantation remain to be estab-
lished. MAGE-11 is coexpressed with AR in human ovarian
granulosa cells3 where it may function in oocyte survival (34).
MAGE-11mRNA levels increasemore than 100-fold in a subset
of patients with castration-recurrent prostate cancer undergo-
ing androgen deprivation therapy. The increase in MAGE-11
during prostate cancer growth results from progressive hypo-
methylation of a CpG island at the transcription start site (37).
Increased levels ofMAGE-11 that increase humanAR signaling
during prostate cancer progression may promote prostate can-
cer cell survival (59). In normal men, increased AR signaling by
MAGE-11 may improve physical strength and survival, and in
women, it may be important for reproductive success.
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